Search results for "Maxim"

showing 10 items of 1236 documents

Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial.

2020

Abstract Ibrutinib, obinutuzumab, and venetoclax demonstrate synergy in preclinical models of mantle cell lymphoma (MCL). OAsIs (NCT02558816), a single-arm multicenter prospective phase 1/2 trial, aimed to determine the maximum tolerated dose of venetoclax in combination with fixed doses of ibrutinib and obinutuzumab, in relapsed MCL patients. At the venetoclax MTD, extension cohorts were opened for relapsed and untreated patients. Safety and efficacy were secondary objectives. Minimal residual disease (MRD) was assessed by allele-specific oligonucleotide quantitative polymerase chain reaction. Between 14 October 2015 and 29 May 2018, 48 patients were enrolled. No dose-limiting toxicity was…

0301 basic medicineMaleNeoplasm Residualmedicine.medical_treatmentImmunoglobulin Variable RegionHematopoietic stem cell transplantationKaplan-Meier EstimateLymphoma Mantle-CellBiochemistryGastroenterologychemistry.chemical_compound0302 clinical medicinePiperidinesObinutuzumabAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesProspective cohort studyAged 80 and overSulfonamidesHematopoietic Stem Cell TransplantationHematologyMiddle AgedCombined Modality TherapyProgression-Free Survival3. Good healthTreatment Outcome030220 oncology & carcinogenesisIbrutinibFemaleImmunoglobulin Heavy Chainsmedicine.medical_specialtyMaximum Tolerated DoseImmunologyAntibodies Monoclonal Humanized03 medical and health sciencesInternal medicinemedicineHumansProgression-free survivalAgedVenetoclaxbusiness.industryAdenineCell Biologymedicine.diseaseBridged Bicyclo Compounds HeterocyclicGenes p53Minimal residual diseaseHematologic Diseases030104 developmental biologychemistryMutationMantle cell lymphomabusinessFollow-Up StudiesBlood
researchProduct

Improved electroless platinum contacts on CdZnTe X- and γ-rays detectors

2020

AbstractPlatinum is a promising candidate for the realization of blocking electrical contacts on cadmium-zinc-telluride (CdZnTe or CZT) radiation detectors. However, the poor mechanical adhesion of this metal often shortens the lifetime of the final device. In this work, a simple and effective procedure to obtain robust platinum contacts by electroless deposition is presented. Microscopical analysis revealed the final thickness and composition of the contact layer and its adhesion to the bulk crystal. The blocking nature of the Pt-CdZnTe junction, essential to obtain low noise devices, was confirmed by current–voltage measurements. The planar Pt-CdZnTe-Pt detectors showed good room temperat…

0301 basic medicineMaterials for devicesMaterials sciencechemistry.chemical_elementlcsh:MedicineElectronCZT detectorELECTRIC-FIELD PROFILE;TRANSIENT-CURRENT;TRANSPORT-PROPERTIESPULSE-SHAPE;CDTE;PERFORMANCE;RESISTIVITY;DEPOSITION;BULKParticle detectorArticle03 medical and health sciences0302 clinical medicinePlanarlcsh:ScienceMultidisciplinarybusiness.industrySettore FIS/01 - Fisica SperimentaleDetectorlcsh:RCarrier lifetimeX-ray and gamma ray detectorSettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)Electrical contactsMaterials scienceFull width at half maximum030104 developmental biologychemistrysemiconductor detectorOptoelectronicslcsh:QbusinessPlatinum030217 neurology & neurosurgeryScientific Reports
researchProduct

A Dirichlet Autoregressive Model for the Analysis of Microbiota Time-Series Data

2021

Growing interest in understanding microbiota dynamics has motivated the development of different strategies to model microbiota time series data. However, all of them must tackle the fact that the available data are high-dimensional, posing strong statistical and computational challenges. In order to address this challenge, we propose a Dirichlet autoregressive model with time-varying parameters, which can be directly adapted to explain the effect of groups of taxa, thus reducing the number of parameters estimated by maximum likelihood. A strategy has been implemented which speeds up this estimation. The usefulness of the proposed model is illustrated by application to a case study.

0301 basic medicineMathematical optimizationMultidisciplinaryArticle SubjectGeneral Computer ScienceComputer scienceMaximum likelihoodQA75.5-76.9501 natural sciencesDirichlet distribution010104 statistics & probability03 medical and health sciencessymbols.namesake030104 developmental biologyAutoregressive modelElectronic computers. Computer sciencesymbols0101 mathematicsTime seriesComplexity
researchProduct

Vertical Root Fracture initiation in curved roots after root canal preparation : a dentinal micro-crack analysis with LED transillumination

2017

Background One of the causative factors of root defects is the increased friction produced by rotary instrumentation. A high canal curvature may increase stress, making the tooth more susceptible to dentinal cracks. The purpose of this study was to evaluate dentinal micro-crack formation with the ProTaper NEXT and ProTaper Universal systems using LED transillumination, and to analyze the micro-crack generated at the point of maximum canal curvature. Material and Methods 60 human mandibular premolars with curvatures between 30–49° and radii between 2–4 mm were used. The root canals were instrumented using the Protaper Universal® and Protaper NEXT® systems, with the aid of the Proglider® syst…

0301 basic medicineMaximum curvatureMaterials sciencebusiness.industryResearchRoot canalMicro cracksDentistry030206 dentistryTransilluminationmedicine.diseaseCurvature:CIENCIAS MÉDICAS [UNESCO]Operative Dentistry and Endodontics03 medical and health sciences030104 developmental biology0302 clinical medicinemedicine.anatomical_structureVertical root fractureUNESCO::CIENCIAS MÉDICASmedicineRotary instrumentationbusinessGeneral Dentistry
researchProduct

GET_PHYLOMARKERS, a software package to select optimal orthologous clusters for phylogenomics and inferring pan-genome phylogenies, used for a critic…

2018

22 Pags.- 3 Tabls.- 7 Figs. Creative Commons License Attribution 4.0 International (CC BY 4.0).

0301 basic medicineMicrobiology (medical)Computer science030106 microbiologylcsh:QR1-502GenomicsLocus (genetics)Context (language use)Computational biologyMicrobiologyGenomelcsh:Microbiologylaw.invention03 medical and health scienceschemistry.chemical_compoundPhylogeneticslawPhylogenomicsRefSeqSpecies delimitationNucleotideCladeMexicoOriginal Researchchemistry.chemical_classificationPhylogenetic treespecies-treePan-genomeStenotrophomonas maltophilia complexgenome-phylogenyphylogenetics030104 developmental biologychemistryMolecular phylogeneticsRecombinant DNAmaximum-likelihoodDNA
researchProduct

Fine metagenomic profile of the Mediterranean stratified and mixed water columns revealed by assembly and recruitment

2018

Background: The photic zone of aquatic habitats is subjected to strong physicochemical gradients. To analyze the fine-scale variations in the marine microbiome, we collected seven samples from a single offshore location in the Mediterranean at 15 m depth intervals during a period of strong stratification, as well as two more samples during the winter when the photic water column was mixed. We were able to recover 94 new metagenome-assembled genomes (MAGs) from these metagenomes and examine the distribution of key marine microbes within the photic zone using metagenomic recruitment. Results: Our results showed significant differences in the microbial composition of different layers within th…

0301 basic medicineMicrobiology (medical)Mediterranean climateStratification (water)MediterraneanBiologyMicrobiologylcsh:Microbial ecology579 - Microbiología03 medical and health sciencesWater columnMediterranean seaMicrobial ecologyMediterranean SeaPhotic zonePhylogenyDeep chlorophyll maximumBacteriaEcologyResearchAquatic ecosystemStenobathicArchaea030104 developmental biologylcsh:QR100-130Deep chlorophyll maximumMetagenomicsSeasonsStratificationWater MicrobiologyMediterraneanPhotic zoneMicrobiome
researchProduct

Phase I multicenter, open-label study to establish the maximum tolerated dose (MTD) of trifluridine/tipiracil (TAS-102) and oxaliplatin combination i…

2018

816 Background: Preclinical evidence suggests improved efficacy when combining trifluridine/tipiracil with oxaliplatin compared to each monotherapy (Nukatsuka, 2015). The primary objective was to determine the MTD and the safety profile of the doublet among mCRC pts who have progressed after at least one prior line of treatment. Methods: Using a 3+3 design, eligible pts received escalating trifluridine/tipiracil doses from 25, 30 to 35 mg/m² bid, days 1–5 q14, together with a fixed dose of oxaliplatin 85 mg/m² (day 1). An intermediate cohort with a lower dose of oxaliplatin (65 mg/m²) plus 35 mg/m² of trifluridine/tipiracil was also tested. Results: Fifteen of 17 enrolled pts were evaluabl…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtybusiness.industryColorectal cancerTrifluridinemedicine.diseaseOxaliplatinstomatognathic diseases03 medical and health scienceschemistry.chemical_compound030104 developmental biology0302 clinical medicineOncologyOpen label studychemistry030220 oncology & carcinogenesisMaximum tolerated doseInternal medicinemedicineIn patientbusinessmedicine.drugTipiracilJournal of Clinical Oncology
researchProduct

Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial.

2017

Abstract Purpose The prognosis is poor for patients with recurrent, platinum-resistant epithelial ovarian cancer (EOC). Evidence suggests that antiangiogenic treatment modalities could play a major role in EOC. A combined therapy consisting of the investigational oral antiangiogenic agent pazopanib and metronomic oral cyclophosphamide may offer a well-tolerable treatment option to patients with recurrent, previously treated EOC. Patients and methods This study was designed as a multicenter phase I trial evaluating the optimal dose as well as activity and tolerability of pazopanib with metronomic cyclophosphamide in the treatment of patients with recurrent, platinum-resistant, previously tre…

0301 basic medicineOncologyDiarrheamedicine.medical_specialtyIndazolesCyclophosphamideMaximum Tolerated DosePlatinum CompoundsCarcinoma Ovarian EpithelialDisease-Free SurvivalPazopanib03 medical and health sciences0302 clinical medicineLiver Function TestsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasms Glandular and EpithelialAdverse effectCyclophosphamideFatigueAgedOvarian NeoplasmsSulfonamidesLeukopeniabusiness.industryObstetrics and GynecologyLeukopeniaMiddle Agedmedicine.diseaseSurgeryRegimen030104 developmental biologyPyrimidinesOncologyTolerabilityDrug Resistance Neoplasm030220 oncology & carcinogenesisFallopian tube cancerFemalemedicine.symptomNeoplasm GradingNeoplasm Recurrence LocalbusinessOvarian cancerNeoplasms Cystic Mucinous and Serousmedicine.drugGynecologic oncology
researchProduct

A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3)

2018

Abstract Background There are limited treatment options for squamous non-small cell lung cancer (sqNSCLC) and prognosis remains poor. The safety and pharmacokinetics (PK) of nintedanib, a triple angiokinase inhibitor, plus cisplatin/gemcitabine as first-line treatment for advanced sqNSCLC patients, were evaluated. Materials and methods A phase I, dose-escalation study administering drugs in a 21-day cycle: cisplatin (75 mg/m2, Day 1), gemcitabine (1250 mg/m2, Days 1 and 8) and nintedanib (Days 2–7, 9–21) were given for 4–6 cycles, followed by monotherapy until disease progression or adverse events (AEs). Two nintedanib doses were tested, 150 mg twice daily (bid) and 200 mg bid, to determine…

0301 basic medicineOncologyMaleCancer ResearchPHARMACOKINETICSIndolesLung NeoplasmsPACLITAXELDeoxycytidineANGIOGENESISSquamouschemistry.chemical_compound0302 clinical medicineNon-small cell lung cancerCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsBIBF 1120Aged 80 and overMiddle AgedPrognosisTreatment OutcomeOncologyPaclitaxelLABEL DOSE-ESCALATION030220 oncology & carcinogenesisNintedanibFemaleCLINICAL-PRACTICE GUIDELINESmedicine.drugPulmonary and Respiratory Medicinemedicine.medical_specialtyBevacizumabMaximum Tolerated DoseNintedanibBEVACIZUMABCONTROLLED-TRIALDisease-Free Survival03 medical and health sciencesPharmacokineticsInternal medicinemedicineHumansAdverse effectAgedNeoplasm StagingTRIPLE ANGIOKINASE INHIBITORCisplatinCARBOPLATINbusiness.industryGemcitabineCarboplatinGemcitabine030104 developmental biologychemistryCisplatinbusinessLung Cancer
researchProduct

Survival of Late Pleistocene Hunter-Gatherer Ancestry in the Iberian Peninsula

2019

The Iberian Peninsula in southwestern Europe represents an important test case for the study of human population movements during prehistoric periods. During the Last Glacial Maximum (LGM), the peninsula formed a periglacial refugium [1] for hunter-gatherers (HGs) and thus served as a potential source for the re-peopling of northern latitudes [2]. The post-LGM genetic signature was previously described as a cline from Western HG (WHG) to Eastern HG (EHG), further shaped by later Holocene expansions from the Near East and the North Pontic steppes [3, 4, 5, 6, 7, 8, 9]. Western and central Europe were dominated by ancestry associated with the ∼14,000-year-old individual from Villabruna, Italy…

0301 basic medicinePleistoceneHuman MigrationPopulationBiologyPrehistòriaGeneral Biochemistry Genetics and Molecular Biology[SHS]Humanities and Social SciencesPrehistory03 medical and health sciences0302 clinical medicinePaleolithicRefugium (population biology)PeninsulaHumansDNA AncientNeolithiceducationMesolithicHunter-gathererComputingMilieux_MISCELLANEOUSAncestryeducation.field_of_studygeographyGenomegeography.geographical_feature_categoryAncient DNALast Glacial MaximumGenome HumanEcologyfood and beverageshumanitiesrespiratory tract diseasesEurope030104 developmental biologyAncient DNASpainIberiaGeneral Agricultural and Biological SciencesMesolithic030217 neurology & neurosurgeryHuman
researchProduct